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Results In total 692 consecutive procedures, 386CA (56%) and 306PCI
(44%) were performed, 380 (55%) via RFA, 232 (34%) via RRA and 80
(11%) via LRA. The CD was lower in the RFA (6.9±11.8∝Sv vs. RRA
26.4±54.1μSv, p<0.001, vs. LRA 9.9±18.5μSv, p<0.001). 
There was no difference in the DAP between LRA and RRA
(34.4±23.8Gycm2 vs. 40.3±28.5Gycm2, p=0.13). 
The RFA demonstrated higher levels (55.3±64.3Gycm2) compared to both
RRA (p=0.03) and LRA (p<0.01).
The adjusted ORE was significantly lower in the RFA (0.17±0.27∝Sv/
Gycm2) compared to the RRA (0.62±0.69∝Sv/Gycm2, p<0.001) or the LRA
group (0.30±0.36∝Sv/Gycm2, p<0.001), as was for the LRA compared to the
RRA (p<0.001).
Conclusions The RFA in CA and PCI is associated with significantly
lower ORE when compared to the RRA or LRA. The LRA is associated with
significantly lower ORE when compared to the RRA.
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Purpose The RAY’ACT project is a nationwide, multicentre survey program
aimed at evaluating patient radiation protection (RP) during coronary angiog-
raphy (CA) and percutaneous coronary interventions (PCI) in French non-uni-
versity public hospitals, which represent >30% of the national activity for PCIs,
and 60% of the emergency cases. We present the updated reference levels based
on the results of the second survey conducted in 2013 (RAY’ACT2).
Methods RP parameters from 48,547 CAs and 40,026 PCIs performed at
61 centres during 2013 and routinely registered in professional software were
extracted and analysed retrospectively. Kerma-area product (KAP), fluoroscopy
time (FT), number of acquired frames (Nb F) and runs (NR), and total Air Kerma
at interventional reference point (KA, r) were analysed separately for CAs and
PCIs (elective and ad hoc pooled). All procedures of the year were included. 
Results The table shows the medians (Q1-Q3) of the RP parameters,
updated RLs based on the 75th percentiles of the values for CA and PCI
(bold), and previous RLs (RAY’ACT1, 2010).
Conclusions Between 2010 and 2013, a 20 to 30% decrease was observed
in medians and Reference Levels (Q3) for main RP parameters, including
KAP and total Air Kerma. 
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Background/Introduction Although transradial access (TRA) is being
increasingly used in interventional cardiology, there are concerns about a pos-
sible increase in radiation exposure as compared to transfemoral access (TFA).
Purpose The aim of this study is the comparison of radiation exposure
parameters between coronary angiography procedures performed via left
radial artery, right radial artery or femoral artery and the detection of factors
that contribute to increased radiation dose.
Methods We analysed collected data on radiation exposure for a total of
733 consecutive diagnostic coronary angiographies (69% in men) excluded
those concerning patients with aortocoronary bypass grafts or those accompa-
nied by aortography or ventriculography. Dose area product (DAP) and fluo-
roscopy time (FT) were used as a means of radiation exposure measurement. 
Results The mean patients’ age was 66.8±10.1 years and BMI
28.4±4.6kg/m2. Femoral access was used in 45% of the procedures, right
radial access (RRA) in 42% and left radial access (LRA) in 13%. 
More diagnostic catheters were used via TFA than TRA (2.24±0.63 vs
1.94±0.83 respectively, p<0.001); LRA was associated with the use of more
diagnostic catheters than RRA. 
TRA was associated with increased FT (4.8±3.5 vs 3.1±2.4 min, p<0.001
but there was no difference regarding FT between RRA and LRA. Hyperten-
sion and the presence of ascending aorta aneurysm were predictors of
increased exposure parameters, especially in TRA, whereas diabetes mellitus
was predictor of increased DAP. The use of 1 or 2 diagnostic catheters was
associated with reduced DAP and FT. 
Conclusion TRA is associated with increased FT. Hypertension and
ascending aorta aneurysm are adversely affecting exposure parameters. With
TRA and especially RRA is feasible the use of fewer diagnostic catheters in
patients undergoing diagnostic coronary angiography. 
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Background Many studies describe a relationship between brittle bones
and cardiovascular disease.
The physiopathology may be explained by the osteoprogerin (OPG) that
protects the vascular wall and inhibits the RANK-RANKL system which is a
strong inhibitor of osteoclasts.Thus it seems interesting to assess the preva-
lence of osteoporosis and osteopenia in patients with a confirmed coronary
heart disease.
Material and Methods This study enrolled 46 patients who underwent a
coronary angiography for chest pain. We identified two groups of patients:
– Group 1: patients with significant coronary artery disease.
– Group 2: patients with normal coronary angiography.
All patients had a physical exam, a phosphocalcic investigation and bone
mineral density (BMD).
Results The mean age of the population was 66.7±6.5 years old .52.17%
were women. Among the 46 patients, 21.7% had an osteoporosis, 41.3% an
osteopenia and 37% had a normal bone mineral density. 52% des 52% of the
studied population had significant coronary artery disease, 48% had a normal
coronary angiography. At the statistical analysis, prevalence of osteoporosis
and osteopenia was significantly higher in group 1 than in group 2 (p<0,001).






KAP (Gy.cm²) 20.9 (11.8-35.7) 27.2 (15.5-45.2)
FT (min) 3.3 (2.1-5.7) 3.7 (2.3-6.3)
Nb Frames 404 (284-566) 553 (388-769) 
KA,r (mGy) 294 (164-498) 421 (240-695)
PCI N=40,026 N=25,356
KAP (Gy.cm²) 45.2 (25.6-77.6) 56.8  (32.8-94.6)
FT (min) 9.8 (6.3-15.4) 10.3 (6.7-16.2)
Nb Frames 676 (465-960) 837 (578-1193)
KA,r (mGy) 747 (421-1285) 1052 (589-1788)
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Conclusion The association between osteoporosis and cardiovascular dis-
ease is a reality. However mechanisms are not well known.Thus it could be
interesting to suggest a DXA to coronary patients and a large cardiovascular
investigation for osteoporotic patients.
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Introduction evaluation of filling pressures and longitudinal systolic left
ventricular function in the acute coronary syndrom (ACS) isn’t common prac-
tice. Our aim is to demonstrate the prognostic of tissuedoppler mitral to ACS.
Material and Methods prospective study of 6months included all patients
admited for STEMI. Exploration of diastole was performd by studying the profile
mitral annulus and the longitudinal systolic function by DTI of left ventricular.
Results A total of 124 patients.the mean age was 61±10years old. A male
predominance of 73%. Hypertension and diabetics was the frequent cardiovas-
cular factor. Elevation of filling pressure was significantly correlated with the
risk of hospital mortality (p<0,05) ans occurence of major cardiovascular
events (p<0,005). A value of S’VG<4cm/s is predictive of the risk of death
and major cardiovacsular event (p<0,05).
Conclusion evaluation with DTI in ACS proves interesting in the risk
stratification to identify groups must benefit from intensive treatment.
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Background Because most randomised trials assessing beta-blocker therapy
after acute myocardial infarction (AMI) antedate the era of reperfusion and
modern secondary prevention, there are discrepancies among guidelines
regarding their use in this setting. We analysed data from the French registry on
ST- and non-ST-elevation Myocardial Infarction (FAST-MI) 2005, to assess the
impact of early prescription and prolonged beta-blocker therapy after AMI.
Methods FAST-MI included 3,670 consecutive patients with AMI
throughout France at the end of 2005. Detailed therapy at discharge and over
follow-up (5 years) was recorded. We studied associations 1) between beta-
blockers at discharge and one-year mortality, 2) between persistence of beta-
blocker therapy at one year and 5-year mortality. Cox multivariate analysis
and propensity score matching were used.
Results Of 2,727 patients with no history of heart failure and no left ven-
tricular dysfunction, 2,168 were prescribed beta-blockers at discharge (80%).
One-year mortality was lower in patients on beta-blockers (4.7% vs 12.2%),
adjusted hazard ratio 0.76, 0.53-1.10. Among the 1,630 patients discharged on
beta-blockers, alive at one year, and with medical prescriptions available, 184
(11%) had stopped beta-blockers. Five-year mortality was 8.8% in patients
who continued beta-blockers, versus 13.0% in those who discontinued.
Adjusted hazard ratio for 5-year death was 1.01 (0.59-1.73). Propensity score
analyses confirmed these findings.
Conclusion Our results suggest that discontinuing beta-blockers beyond one
year has no deleterious impact, but that early beta-blocker treatment may be ben-
eficial. Until further randomised trials are performed, these data can provide useful
information for future recommendations on beta-blocker use after AMI. 
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Background Current guidelines recommend a low-density lipoprotein cho-
lesterol (LDL-C) target of <1.8mmol/l for coronary patients and the adminis-
tration of high potency statin therapy. 
Purpose Our study documents real world lipid target achievement, including
distance to target, among patients with stable coronary heart disease (CHD) and
patients surviving an acute coronary syndrome (ACS) event in Europe.
Methods DYSIS II is a multicountry, observational cross-sectional chart
review conducted in 257 sites throughout Belgium, France, Germany, Greece,
Ireland, Italy, and Russia. Two distinct patient cohorts were enrolled: patients
surviving an ACS event and patients diagnosed with stable CHD. Full lipid
profiles were available within 24 hours of hospital admission for ACS patients
and 0-12 months prior to enrollment for CHD patients. Patients were on lipid-
lowering therapy (LLT) ≥3 months and not participating in clinical trials
involving medication. Patient characteristics, risk factors, treatment patterns,
and laboratory values were collected. LDL-C target achievement was assessed
based on ESC/EAS guidelines.
Results 880 ACS and 2778 CHD patients currently on LLT were enrolled
in Europe from 2012 to 2014. Only 23.2% (n=204) ACS and 29.6% (n=821)
CHD patients achieved and LDL-C<1.8mmol/l, with median distance to LDL-
C target in patients not a goal being 0.9mmol/l (IQR 0.4, 1.5) in ACS and
0.6mmol/l (IQR 0.3, 1.1) in CHD patients.
Conclusion Three out of four coronary patients did not achieve the recom-
mended LDL-C target, even while being treated with LLT, primarily statin
monotherapy.
Low potency statin treatment was found in both patient cohorts, despite the
high risk of our patient population and the need for more intense LLT (as
stressed by our distance to target findings).
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Atorvastatin equivalent dose (mg/day)
Statin monotherapy
Statin + ezetimibe
Statin + other non-statin 
(fibrates, omega 3 fatty acids)
Non-statin monotherapy
4.4±1.2
2.6±1.0
1.6±0.9
1.1±0.3
3.3±1.2
22±17
87.2%
6.4%
2.4%
3.8%
4.1±1.0
2.3±0.8
1.5±0.8
1.2±0.4
2.9±0.9
27±20
79.8%
11.6%
6.7%
2.0%
